Supernus Pharmaceuticals, Inc.
SUPN
Rank in Stocks
#6738
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
Share Price
$27.62
Last synced: 2026-11-09
Market Cap
$1.61B
Change (1 day)
5.58%
Change (1 year)
-40.10%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Supernus Pharmaceuticals, Inc. (SUPN)
Category
Healthcare
Operating Margin for Supernus Pharmaceuticals, Inc. (SUPN)
Operating Margin as of November 2026 TTM: -3.51%
According to Supernus Pharmaceuticals, Inc.'s latest financial reports, its current operating margin (TTM) is -3.51%. At the end of 2025 the company had an operating margin of 21.39%.
Operating Margin history for Supernus Pharmaceuticals, Inc. from 2007 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -3.51% | -116.41% |
| 2025 | 21.39% | 73.34% |
| 2024 | 12.34% | -1,518.39% |
| 2023 | -0.87% | -112.59% |
| 2022 | 6.91% | -53.44% |
| 2021 | 14.84% | -55.54% |
| 2020 | 33.38% | -11.76% |
| 2019 | 37.83% | 7.08% |
| 2018 | 35.33% | 7.29% |
| 2017 | 32.93% | 30.57% |
| 2016 | 25.22% | 106.21% |
| 2015 | 12.23% | -38.39% |
| 2014 | 19.85% | -103.85% |
| 2013 | -515.18% | -81.92% |
| 2012 | -2,849.26% | -39.40% |
| 2011 | -4,701.37% | -87.58% |
| 2010 | -37,851.89% | -357,530.50% |
| 2009 | 10.59% | -103.64% |
| 2008 | -290.93% | -35.34% |
| 2007 | -449.92% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 19.41% | -105.53% |
DE
|
|
| 19.68% | -105.61% |
DE
|
|
| 13.26% | -103.78% |
JP
|
|
| 17.08% | -104.87% |
CH
|
|
| 14.92% | -104.25% |
IL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Supernus Pharmaceuticals, Inc.'s operating margin
What is Supernus Pharmaceuticals, Inc.'s operating margin?
Supernus Pharmaceuticals, Inc.'s operating margin is -3.51%, as of Nov 2026.
What was Supernus Pharmaceuticals, Inc.'s operating margin in 2025?
In 2025, Supernus Pharmaceuticals, Inc.'s operating margin was 21.39%, compared with 12.34% in 2024.
How has Supernus Pharmaceuticals, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Supernus Pharmaceuticals, Inc.'s operating margin was highest in 2020 (33.38%) and lowest in 2023 (-0.87%).
How does Supernus Pharmaceuticals, Inc.'s operating margin compare with similar companies?
Supernus Pharmaceuticals, Inc.'s operating margin (-3.51%) is lower than that of all 5 similar companies listed above. The highest among them is Merck KGaA, with 19.68%.